September 1st 2025
The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.
Cardiometabolic Diseases and Dementia Risk Show Dose-dependent Relationship in Large Twin Study
January 13th 2023For each cardiometabolic disease, the risk of all-cause dementia rose by 42%; the risk rose 26% for Alzheimer disease and 64% for vascular dementia. Temporal onset and genetics play key roles.